“OriGene values BioCheck’s unique combination of novel FDA approved diagnostic products and its custom immunoassay development platform. " Commented Dr. Weiwu He, CEO of OriGene.
Rockville, MD (PRWEB) February 26, 2014
The acquisition of BioCheck expands OriGene’s IVD portfolio and capabilities for future product development, leveraging its current leading Chinese diagnostics channels. China’s IVD market is among the fastest growing in the world, and from recent annual growth rates, it is predicted to be the world’s second largest IVD market by 2017. The market growth in this sector will be driven by an increasing demand for new diagnostic tests, for which OriGene and BioCheck will be uniquely positioned to deliver.
With over 45 years of collective experience, BioCheck has been pioneering the development of custom immunoassays for colorectal cancer, breast cancer, heart disease, and several infectious diseases. Commenting on the acquisition, OriGene’s CEO, Wei-Wu He, Ph.D., stated, “OriGene values BioCheck’s unique combination of novel FDA approved diagnostic products and its custom immunoassay development platform. Gaining such capacity is crucial to OriGene’s mission to empower the Chinese IVD market with more specific and sensitive products for responsive decision making and improved health outcomes. We welcome BioCheck into the OriGene family.” In a related statement, John Chen, Ph.D., President and Founder of BioCheck, said, “We believe that the joint force of BioCheck’s diagnostic product development capacity and OriGene’s broad reach into China’s clinical market will greatly enhance our ability to realize our founding vision of delivering novel IVD products to the health care markets. Both companies share a history of success in the diagnostics market, and together we are poised for growth through our plans to deploy new IVD products for the fast growing Chinese market.”